Bernstein Maintains Outperform on CVS Health, Raises Price Target to $106

Benzinga Newsdesk www.benzinga.com Positive 86.4%

Neg 0% Neu 0% Pos 86.4%

Bernstein analyst Lance Wilkes maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $94 to $106.